Thanks Pete.
Upon reading the article it seems to me that we could equally qualify for Orphan Drug Designation as well as Breakthrough Therapy.
I'd like to know if there is a reason not to pursue both avenues.
If we achieve FDA approval for Breakthrough Therapy then surely an interested party would be eager to advance a proposal to PAA
Ann: PharmAust to present at Emerging ASX Gems Conference, page-47
-
- There are more pages in this discussion • 36 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.0¢ |
Change
0.005(2.44%) |
Mkt cap ! $83.14M | |||
| Open | High | Low | Value | Volume |
| 21.5¢ | 22.0¢ | 21.0¢ | $262.8K | 1.225M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 25394 | 21.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.5¢ | 44560 | 3 |
View Market Depth
| Last trade - 16.10pm 24/06/2024 (20 minute delay) ? |
| PAA (ASX) Chart |